Eli Lilly and Co  

(Public, NYSE:LLY)   Watch this stock  
Find more results for LLY
82.06
+0.72 (0.89%)
Apr 28 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 81.20 - 82.25
52 week 64.18 - 86.72
Open 81.37
Vol / Avg. 3.16M/3.94M
Mkt cap 91.35B
P/E 39.85
Div/yield 0.52/2.53
EPS 2.06
Shares 1.10B
Beta 0.34
Inst. own 78%
Jul 25, 2017
Q2 2017 Eli Lilly and Co Earnings Release - 9:30AM EDT - Add to calendar
Jul 25, 2017
Q2 2017 Eli Lilly and Co Earnings Call - 9:00AM EDT - Add to calendar
Jun 3, 2017
Eli Lilly and Co Oncology Update Conference Call - 7:00PM EDT - Add to calendar
May 1, 2017
Eli Lilly and Co Annual Shareholders Meeting - 11:00AM EDT - Add to calendar
Apr 25, 2017
Q1 2017 Eli Lilly and Co Earnings Release
Apr 25, 2017
Q1 2017 Eli Lilly and Co Earnings Call
Mar 27, 2017
Eli Lilly and Co at Sachs Associates Neuroscience BioPartnering & Investment Forum
Mar 7, 2017
Eli Lilly and Co at Cowen Health Care Conference - Webcast
Feb 16, 2017
Eli Lilly and Co at Leerink Partners Global Healthcare Conference - Webcast
Jan 31, 2017
Q4 2016 Eli Lilly and Co Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -2.12% 12.90%
Operating margin 0.88% 16.30%
EBITD margin - 25.29%
Return on average assets - 7.36%
Return on average equity - 19.16%
Employees 41,975 -
CDP Score - A-

Address

Lilly Corporate Ctr, Drop Code 1112
INDIANAPOLIS, IN 46285
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Officers and directors

John C. Lechleiter Ph.D. Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
David A. Ricks Chairman of the Board, President, Chief Executive Officer
Age: 49
Bio & Compensation  - Reuters
Derica W. Rice Chief Financial Officer, Executive Vice President - Global Services
Age: 52
Bio & Compensation  - Reuters
Maria A. Crowe President - Manufacturing Operations
Age: 57
Bio & Compensation  - Reuters
Jan M. Lundberg Ph.D. Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Age: 63
Bio & Compensation  - Reuters
Melissa Stapleton Barnes Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Age: 48
Bio & Compensation  - Reuters
Michael J. Harrington Senior Vice President, General Counsel
Age: 54
Bio & Compensation  - Reuters
Stephen F. Fry Senior Vice President - Human Resources and Diversity
Age: 51
Bio & Compensation  - Reuters
Enrique A. Conterno Senior Vice President and President - Lilly Diabetes and President - Lilly USA
Age: 50
Bio & Compensation  - Reuters
Susan Mahony Ph.D. Senior Vice President and President - Lilly Oncology
Age: 52
Bio & Compensation  - Reuters